Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
<p>Abstract</p> <p>Background</p> <p>Mutations within the tumor suppressor <it>TP53 </it>gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy....
Main Authors: | Abolmaali Nasreddin D, Tokalov Sergey V |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-02-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/57 |
Similar Items
-
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
by: Erin K Crane, et al.
Published: (2015-01-01) -
Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2
by: Dasom Kim, et al.
Published: (2023-12-01) -
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
by: Arya, A, et al.
Published: (2010) -
The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise.
by: Krzysztof Puszynski, et al.
Published: (2014-12-01) -
Discovering putative protein targets of small molecules : a study of the p53 activator Nutlin
by: Nguyen, Minh N., et al.
Published: (2021)